About Dr Grant Logan

Grant is keenly interested in gene therapy and the immune system both to understand how immunity affects gene delivery and to also exploit this powerful 'pressure point' to drive therapeutic responses. More broadly he is interested in the development of virus-based gene delivery technologies for therapeutic gene delivery and genome editing.

Grant has over twenty years experience in the design, synthesis and application of viral vector systems for therapeutic gene delivery and in vivo genome editing. His publications cover fundamental aspects of gene therapy, cell biology and the immunobiology of gene therapy. This includes areas such as genetic vaccines, cellular reprogramming, gene correction by gene addition or gene editing and the development of gene therapy treatments for immunodeficiencies and metabolic liver disease. Notably, this has been in both the research laboratory in Australia and the biotech industry of London affording valuable international experience in the clinical translation of gene therapies.

Grant has (co-)authored >20 research papers and/or book chapters over his research career with most reflecting his strong immunological interest and development of gene therapies targeting the immune system, including its modulation for therapeutic benefit, as a genetic disease target (SCID-X1) and its capacity to influence gene delivery. He is also a credited inventor on patents for CAR-T treatments for blood malignancies due to his instigation of an industry collaboration and co-development of innovative immunotherapies. His research has also focused on targeting the liver using AAV. This recently culminated in one of his most significant papers published in Nature Genetics in recognition of its far-reaching importance as it impacts safe clinical utility of recombinant adeno-associated virus (AAV) as a gene delivery system and reveals new aspects of virus biology. Importantly, it also identifies a potential mechanism behind a controversial finding implicating AAV in cancer, its first disease-association since discovery in 1966. Recognising the importance of industry experience, he recently gained invaluable experience from a secondment to a Wellcome-backed biotech company in London whose mission is to translate and commercialise AAV gene therapies.

Selected publications

1) Logan G.J., Dane A.P., Hallwirth C.V., Smyth C.M. Wilkie E.E., Amaya A.K. Zhu E., Khandekar N., Ginn S.L., Liao S., Cunningham S.C., Sasaki N., Tam P.P.L., Russell D.W., Lisowksi L., & Alexander I.E. A novel liver-specific enhancer-promoter element in the wild-type AAV2 genome provides a mechanism for AAV participation in the pathogenesis of human hepatocellular carcinoma. Nature Genetics, Aug;49(8):1267-1273. epub 19th June 2017.
2) Gray P.E.A., Logan G.J., Alexander I.E., Poulton S., Roscioli T. & Ziegler J. (2015) A novel intronic splice site deletion of the IL-2 receptor common gamma chain results in expression of a dysfunctional protein and T-cell positive X-linked Severe combined immunodeficiency. International Journal of Immunogenetics. 42(1):11-14. ePub 28th November 2014.
3) Kok C.Y., Cunningham S.C., Carpenter K.H., Dane A.P., Logan G.J., Kuchel P.W. and Alexander I.E. (2013) Adeno-associated virus-mediated rescue of neonatal lethality in arginosuccinate sythestase-deficient mice. Molecular Therapy 21(10):1823-31. ePub 2nd July 2013.
4) Logan G.J. and Alexander I.E. (2012) Adeno-associated virus vectors: immunobiology and potential use for immune modulation. Current Gene Therapy 12(4): 333-43.
5) Sharland A., Logan G.J., Bishop A. and Alexander I.E. (2010) Liver-directed gene expression using recombinant AAV 2/8 vectors- a tolerogenic strategy for gene therapy? Discovery Medicine 9(49): 519-27
6) Logan G.J., Wang L., Zheng M, Coppel .L. and Alexander I.E. (2010) Antigen fusion with C3d3 augments or inhibits humoral immunity to AAV genetic vaccines in a transgene-dependent manner. Immunology and Cell Biology 88(2): 228-32, ePub 24th November 2009.
7) Logan G.J., Wang L., Zheng M., Coppel R.L. and Alexander I.E. (2008) Antigen-specific humoral tolerance or immune augmentation induced by intramuscular delivery of adeno-associated viruses encoding CTLA4-Ig-antigen fusion molecules. Gene Therapy 16(2): 200-10 epub 27th November 2008.
8) Smyth C.M., Ginn S.L., Deakin C.T., Logan G.J. and Alexander I.E. (2007) Limiting c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood 110(1): 91-98, epub 15th March 2007.
9) Logan G.J., Wang L., Zheng M., Cunningham S.C., Coppel R.L. and Alexander I.E. (2007) AAV vectors encoding malarial antigens stimulate transgene-specific immunity but do not protect from parasite infection. Vaccine 25(6): 1014-1022, epub 9th October 2006.
10) Logan G.J., Smyth C.M.F., Earl J.W., Zaikina I., Rowe P.B., Smythe J.A. and Alexander I.E. (2002) HeLa cells co-cultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase (IDO) activity. Immunology 105(4): 478-487.